Transmembrane Glycoprotein

Transmembrane glycoproteins are important components of cell membranes and are characterized by oligosaccharide chains covalently linked to polypeptide chains. Glycosylation sites are mainly located in their extracellular regions, achieved by N-linked glycosylation (linked to asparagine residues) or O-linked glycosylation (linked to serine or threonine residues). Sugar chains not only provide structural stability to proteins but also confer functional specificity. Many transmembrane glycoproteins are receptors, such as G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). Most （clusters of differentiation）CD molecules are also transmembrane glycoproteins expressed on the surface of antigen-presenting cells^[1]^[2].

References:

[1]. L Franco, et al. The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes. FASEB J. 1998 Nov;12(14):1507-20. [Content Brief]

[2]. Kumi Oshima, et al. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002 May 22;519(1-3):1-7. [Content Brief]

Transmembrane Glycoprotein Related Products (368):

By Effects:	Inhibitors (229) Agonists (7) Ligands (14) Antagonists (7) Activators (10) Modulators (5)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P10184

CD36 Peptide P (93-110), Cys conjugated	Inhibitor
CD36 Peptide P (93-110), Cys conjugated is a Cys labelled CD36 Peptide, and can block binding of CD36 to immobilized thrombospondin and partially inhibited collagen-induced platelet aggregation.

HY-P990611

KRN-330
KRN-330 is a humanized antibody expressed in CHO cells, targeting GPA33. KRN-330 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for KRN-330 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991895

PLG-101	Inhibitor
PLG-101 is a human anti-CD8 antibody. PLG-101 can be used in research on acute myocardial infarction .

HY-P990234

Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3)	Inhibitor
Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse ICOSL/CD275. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) is a chimeric antibody of the original HK5.3 antibody (HY-P990123). Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) contains the LALA-PG mutation region. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) can neutralize ICOSL. Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) can be used for researches of inflammation and infection.

HY-179288

TPST2-IN-1	Inhibitor
TPST2-IN-1 is a potent and selective TPST2 inhibitor with an IC₅₀ of 946 nM and a Ka of 19.4 μM. TPST2-IN-1 increases the phosphorylation of Stat1 and upregulates the IFNγ-responsive gene CXCL10 by inhibiting TPST2 activity.TPST2-IN-1 exhibits anti-tumor activity and enhances T cell-mediated antitumor immunity characterized by increased infiltration of effector CD8⁺ T cells. TPST2-IN-1 can be used for the research of cancer, such as colon cancer.

HY-P991808

Anti-Mouse CD90 Antibody (HK2.1)	Inhibitor
Anti-Mouse CD90 Antibody (HK2.1) reacts with the mouse CD90. Anti-Mouse CD90 Antibody (HK2.1) has been implicated in activation of T-cells. Recommend Isotype Controls: Rat IgG2c.

HY-P992210

Anti-CD326 Antibody (17-1A)
Anti-CD326 Antibody (17-1A) is a human monoclonal antibody targeting CD326. Anti-CD326 Antibody (17-1A) can be used in cancer research. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).

HY-P992218

Anti-CHRDL-1 Antibody
Anti-CHRDL-1 Antibody is a monoclonal antibody that targets CHRDL-1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CHRDL-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P3967

Thymopoietin i/ii (29-41) (bovine)
Thymopoietin i/ii (29-41) (bovine) is a peptide corresponding to positions 29-41 of bovine thymopoietin II. Thymopoietin i/ii (29-41) (bovine) is a neuromuscular blocker.

HY-P991093

NGM-707	Inhibitor
NGM-707 is a humanized monoclonal antibody that blocks ILT2 and ILT4 receptors. NGM-707 has the potential for the study of advanced and metastatic solid tumors.

HY-P991918

KHK2840	Agonist
KHK2840 is a potent CD40 agonist with a K_d value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma.

HY-P991892A

IT1208 (FUT8-KO)	Inhibitor
IT1208 (FUT8-KO) is a humanized anti-CD4 monoclonal IgG1 antibody that has knocked out the fucosyltransferase 8 gene (FUT8). It exhibits enhanced antibody-mediated cytotoxicity (ADCC) effect. IT1208 (FUT8-KO) can effectively eliminate CD4+ T cells in vivo and shows controllable safety. IT1208 (FUT8-KO) can be used in related research on colon cancer.

HY-P991378

MORAb-066	Inhibitor
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.

HY-P991777

Anti-Mouse CD86/B7-2 Antibody (2D10)	Inhibitor
Anti-Mouse CD86/B7-2 Antibody (2D10) reacts with mouse CD86 (B7-2). Anti-Mouse CD86/B7-2 Antibody (2D10) reduces IL-4 production in T cells. Recommend Isotype Controls: Rat IgG2b kappa, Isotype Control (HY-P990682).

HY-P992483

VIS832	Inhibitor
VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma.

HY-P991387

AGEN1307	Inhibitor
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research.

HY-P992441

PHST001	Inhibitor
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.

HY-P11033

Pep2 Peptide	Ligand
Pep2 Peptide (also known as scavenger receptor B2) is a peptide ligand for the transmembrane glycoprotein CD36. Pep2 Peptide selectively binds to CD36 over HAS, IgG and CD44. Pep2 Peptide can be studied in research on enhancing delivery of anticancer agent.

HY-P991810

Anti-Mouse Ly-6C Antibody (HK1.4)	Inhibitor
Anti-Mouse Ly-6C Antibody (HK1.4) reacts with the mouse Ly-6C. Ly-6C antigens are encoded by a complex multigene family and have primarily been defined as novel T cell-activating determinants.

HY-P10593

Influenza A NP (383-391) (HLA-B27)
Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. Influenza A NP (383-391) (HLA-B27) is a broadly immunogenic CD4+ T helper cell epitope that enhances CD8+ cytotoxic T lymphocyte (CTL) responses. Influenza A NP (383-391) (HLA-B27) can be used in breast cancer research.

Name
Email *

	Sorry, but the email address you supplied was invalid.